New England Research & Management’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.26M | Buy |
3,556
+403
| +13% | +$412K | 1.66% | 14 |
|
|
2026
Q1 | $2.9M | Buy |
3,153
+777
| +33% | +$788K | 1.23% | 21 |
|
|
2025
Q4 | $2.55M | Sell |
2,376
-65
| -3% | -$62.2K | 1.12% | 28 |
|
|
2025
Q3 | $1.86M | Sell |
2,441
-360
| -13% | -$268K | 0.86% | 34 |
|
|
2025
Q2 | $2.18M | Buy |
2,801
+90
| +3% | +$69.9K | 1.04% | 27 |
|
|
2025
Q1 | $2.24M | Buy |
2,711
+310
| +13% | +$258K | 1.14% | 24 |
|
|
2024
Q4 | $1.85M | Sell |
2,401
-205
| -8% | -$170K | 0.94% | 31 |
|
|
2024
Q3 | $2.31M | Buy |
2,606
+650
| +33% | +$584K | 1.08% | 27 |
|
|
2024
Q2 | $1.77M | Sell |
1,956
-225
| -10% | -$180K | 0.85% | 41 |
|
|
2024
Q1 | $1.7M | Sell |
2,181
-554
| -20% | -$394K | 0.83% | 38 |
|
|
2023
Q4 | $1.59M | Buy |
2,735
+1,045
| +62% | +$610K | 0.84% | 40 |
|
|
2023
Q3 | $908K | Sell |
1,690
-105
| -6% | -$54.1K | 0.52% | 71 |
|
|
2023
Q2 | $842K | Sell |
1,795
-1,000
| -36% | -$419K | 0.49% | 72 |
|
|
2023
Q1 | $960K | Buy |
2,795
+1,300
| +87% | +$438K | 0.56% | 65 |
|
|
2022
Q4 | $547K | Hold |
1,495
| – | – | 0.31% | 103 |
|
|
2022
Q3 | $483K | Buy |
1,495
+210
| +16% | +$66.5K | 0.3% | 103 |
|
|
2022
Q2 | $417K | Sell |
1,285
-149
| -10% | -$44.7K | 0.24% | 116 |
|
|
2022
Q1 | $411K | Buy |
1,434
+124
| +9% | +$31.9K | 0.21% | 123 |
|
|
2021
Q4 | $362K | Hold |
1,310
| – | – | 0.18% | 133 |
|
|
2021
Q3 | $303K | Sell |
1,310
-1,660
| -56% | -$410K | 0.16% | 147 |
|
|
2021
Q2 | $682K | Buy |
2,970
+1,580
| +114% | +$317K | 0.35% | 96 |
|
|
2021
Q1 | $260K | Sell |
1,390
-4,275
| -75% | -$836K | 0.14% | 151 |
|
|
2020
Q4 | $956K | Sell |
5,665
-6,225
| -52% | -$929K | 0.59% | 60 |
|
|
2020
Q3 | $1.76M | Buy |
+11,890
| New | +$1.84M | 1.27% | 20 |
|
|
2020
Q2 | – | Sell |
-8,390
| Closed | -$1.16M | – | 154 |
|
|
2020
Q1 | $1.16M | Sell |
8,390
-4,185
| -33% | -$575K | 0.99% | 30 |
|
|
2019
Q4 | $1.65M | Sell |
12,575
-275
| -2% | -$31.9K | 1.11% | 23 |
|
|
2019
Q3 | $1.44M | Buy |
12,850
+3,650
| +40% | +$406K | 1.04% | 23 |
|
|
2019
Q2 | $1.02M | Buy |
+9,200
| New | +$1.08M | 0.69% | 48 |
|
|
2018
Q4 | – | Sell |
-2,650
| Closed | -$284K | – | 173 |
|
|
2018
Q3 | $284K | Hold |
2,650
| – | – | 0.18% | 127 |
|
|
2018
Q2 | $226K | Sell |
2,650
-1,400
| -35% | -$115K | 0.15% | 152 |
|
|
2018
Q1 | $313K | Buy |
4,050
+1,200
| +42% | +$96.6K | 0.21% | 135 |
|
|
2017
Q4 | $241K | Sell |
2,850
-1,450
| -34% | -$123K | 0.17% | 133 |
|
|
2017
Q3 | $368K | Hold |
4,300
| – | – | 0.27% | 103 |
|
|
2017
Q2 | $354K | Buy |
+4,300
| New | +$351K | 0.26% | 113 |
|
|
2017
Q1 | – | Sell |
-5,440
| Closed | -$400K | – | 177 |
|
|
2016
Q4 | $400K | Buy |
+5,440
| New | +$405K | 0.31% | 108 |
|
|
2016
Q3 | – | Sell |
-7,400
| Closed | -$583K | – | 176 |
|
|
2016
Q2 | $583K | Buy |
+7,400
| New | +$557K | 0.5% | 64 |
|
|
2014
Q1 | – | Sell |
-12,075
| Closed | -$616K | – | 149 |
|
|
2013
Q4 | $616K | Buy |
+12,075
| New | +$605K | 0.59% | 65 |
|
Other funds holding LLY
SC
New England Research & Management's LLY Position: Q2 2026 in Review
New England Research & Management increased its Eli Lilly (LLY) stake by 13% in Q2 2026, buying an estimated $412K and bringing the position to 3,556 shares worth $4.26M. The position accounts for 1.66% of the portfolio, ranked #14.
New England Research & Management first reported a position in LLY in Q4 2013 and has held it in 37 quarters since. 2,247 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- New England Research & Management held 3,556 shares of Eli Lilly worth $4.26M as of Q2 2026.
- New England Research & Management bought 403 Eli Lilly shares in Q2 2026, an estimated $412K.
- Eli Lilly made up 1.66% of New England Research & Management's portfolio in Q2 2026, its #14 holding.
- New England Research & Management first reported a position in Eli Lilly in Q4 2013 and has held it in 37 quarters since.
- 2,247 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on New England Research & Management's 13F filing for Q2 2026, filed 9 Jul 2026.